Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia

During the last few years many Checkpoint kinase 1/2 (Chk1/Chk2) inhibitors have been developed for the treatment of different type of cancers. In this study we evaluated the efficacy of the Chk 1/2 inhibitor prexasertib mesylate monohydrate in B-/T- cell progenitor acute lymphoblastic leukemia (ALL...

Descripción completa

Detalles Bibliográficos
Autores principales: Rorà, Andrea Ghelli Luserna Di, Iacobucci, Ilaria, Imbrogno, Enrica, Papayannidis, Cristina, Derenzini, Enrico, Ferrari, Anna, Guadagnuolo, Viviana, Robustelli, Valentina, Parisi, Sarah, Sartor, Chiara, Abbenante, Maria Chiara, Paolini, Stefania, Martinelli, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288194/
https://www.ncbi.nlm.nih.gov/pubmed/27438145
http://dx.doi.org/10.18632/oncotarget.10535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5288194/
https://www.ncbi.nlm.nih.gov/pubmed/27438145
http://dx.doi.org/10.18632/oncotarget.10535

Ejemplares similares